Cancer
Also known as: Carcinoma, Malignancy, Neoplasms, Tumor, Neoplasia
Methodology & AI Transparency ⓘ
Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is cancer? Cancer is not just one disease but many diseases.
- 2 Real-world patient consensus: Diagnostic registry D48.19: Cancer is managed within Cancer & Oncology (aka Carcinoma).
- 3 Typical cash cost range: Workup highlights for Cancer (D48.19): multidisciplinary tumor-board planning in Cancer (D48.19: (surgery).
- 4 Top reported side effects / signs: Longitudinal Cancer monitoring tracks Complete Blood Count in Cancer (D48.19: (ANC, Hemoglobin, Platelets)) toward Safe hematologic reserve (D48.19).
Ask our AI Specialists anything about Cancer
What Is Cancer?
What is cancer? Cancer is not just one disease but many diseases. Cancer begins in your cells, which are the building blocks of your body. Usually, your body forms new cells as needed, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer, while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of your body. The spread of cancer from one part of the body to another is called metastasis.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Cancer (D48.19) center on local tissue remodeling [Cancer D48.19]. Cross-referenced with NIH MeSH (Neoplasms), targeted cancer & oncology interventions aim to normalize Complete Blood Count in Cancer (D48.19: (ANC, Hemoglobin, Platelets)).
Common Symptoms & Clinical Signs
- • Exposure to ultraviolet (UV) rays from the sun
- • Physical inactivity
- • Presentation of Cancer (D48.19): persistent painless lump, in Cancer (D48.19: non-healing ulcer/mole change,)
- • Secondary Cancer clinical sign: unintended weight loss [Cancer D48.19]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D48.19 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Cancer (D48.19: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (D48.19) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Cancer (D48.19: Organ Function Panel) | Preserved renal/hepatic clearance (D48.19) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Cancer (D48.19: Genomic Staging) | Guideline-concordant surveillance (D48.19) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cancer
Treatment selection for Cancer depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Integrating NCCN and LATITUDE in metastatic castration-sensitive prostate cancer:: What a 1,052-Participant Study Found While further stratification by metastasis timing suggested no clear survival benefit in the double low synchronous subgroup, wide CIs indicate substantial uncertainty. World journal of urology • 2026-08-19 • Phase III Randomized Trial | N = 1,052 | 96/100 | PMID 42616151 ↗ |
| New Insights on Age-related real-world benefits and safety of Darolutamide Plus: What a 1,086-Participant Study Found In the 219 patients aged ≥75 yr in ARASENS, darolutamide demonstrated improved efficacy versus placebo and favorable safety, consistent with the findings in patients aged <75 yr. European urology oncology • 2026-06-15 • Phase III Randomized Trial | N = 1,086 | 96/100 | PMID 41193271 ↗ |
| New Insights on Veliparib concomitant with first-line chemotherapy and as maintenance therapy in: What a 1,140-Participant Study Found No OS or DRS benefit of addition of veliparib to platinum-based chemotherapy and continued as maintenance therapy was detected in this study, despite an observed. European journal of cancer (Oxford, England : 1990) • 2025-07-25 • Phase III Randomized Trial | N = 1,140 | 96/100 | PMID 40561681 ↗ |
| New Insights on Development and validation of a multivariable prognostic model in de novo: What a 1,058-Participant Study Found A prognostic model for men with de novo mCSPC was developed and validated in an independent testing set. Prostate cancer and prostatic diseases • 2023-03-15 • Phase III Randomized Trial | N = 1,058 | 96/100 | PMID 35790787 ↗ |
| New Insights on Effect of concomitant statin treatment in postmenopausal patients with hormone: What a 3,420-Participant Study Found According to this analysis, hydrophilic statins showed a detrimental effect on DFS in the main model, which was attenuated after correction for confounders. ESMO open • 2022-04-15 • Phase III Randomized Trial | N = 3,420 | 96/100 | PMID 35334418 ↗ |
Cancer Patient Community & “People Like Me” Threads
Filter Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.